Interviews
In this article, we explore the crucial role of shared decision-making in HIV treatment and hear from David Hardy (Johns…
In this interview we speak to Keith Kaye, from the University of Michigan (MI, USA) about the RESTORE-IMI 2 study, its results and why ICU patients represent an unmet need.
Sepsis, a condition associated with significant morbidity and mortality, has been increasingly associated with the gut microbiome. In this interview…
Take a look behind the scenes of a recent Future Microbiology review, entitled ‘Anti-Candida activity of existing antibiotics and their derivatives when used alone or in combination with antifungals’ as we ask the authors about Candida infections, the potential repurposing of antibiotics and the future of this field.
In this interview we speak to Pinaki Panigrahi about his work using probiotics as a preventative strategy against sepsis in neonates. In addition, he comments on the impact of probiotics for other infections and some of the skepticism surrounding some microbiome research.
What role might the healthcare environment play in infections? And how could this be mitigated? We speak to Stephanie Dancer about the healthcare environment and its role in healthcare-associated infections.
In this Ask The Experts we talk to two experts about issues surrounding healthcare-associated infections and infection prevention and control, including the role of surveillance, the involvement of patients and the importance of behavior change.
In this interview, Paul Rowley (University of Idaho, ID, USA) speaks about his research identifying novel antifungal proteins from Saccharomyces cerevisiae yeasts and whether these could be translated into the medications of the future.
Take a look behind the scenes of a recent Future Microbiology review, entitled ‘An update on drug repurposing: Is it useful for tacking antimicrobial resistance?’ as we ask the authors about what challenges and limitations drug repurposing faces, in addition to why this strategy could be a promising alternative to the traditional drug discovery pipeline.
In this interview we speak to Michael Bachman (University of Michigan MI, USA) about his research on the factors involved in Klebsiella colonization and infection, and whether these could be used to stratify high-risk patients in the future.
